Curated News
By: NewsRamp Editorial Staff
August 10, 2026
Telomir-Zn Shows Promise in Prostate and Triple-Negative Breast Cancer
TLDR
- Telomir-Zn's peer-reviewed data shows superior tumor suppression in TNBC and prostate models, advancing Telomir Pharmaceuticals' pipeline advantage.
- Telomir-Zn depletes intracellular iron and copper to inhibit histone demethylases, selectively killing iron-dependent TNBC cells and reactivating tumor suppressors.
- Telomir-Zn targets cancer cells while sparing normal cells, offering hope for more effective and less toxic breast and prostate cancer treatments.
- A novel metal-modulating drug, Telomir-Zn, fights cancer by altering iron and copper levels, a surprising twist in oncology research.
Impact - Why it Matters
This news matters because it represents a significant step forward in the fight against triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of cancer. The preclinical data suggests that Telomir-Zn could offer a novel therapeutic approach that selectively targets cancer cells while sparing healthy tissue, potentially leading to more effective and less toxic treatments. For patients and healthcare providers, this could mean new hope for improved outcomes and quality of life. Additionally, the successful publication of these findings supports the advancement of Telomir-Zn into clinical trials, bringing us closer to a new treatment option for a disease that currently has limited targeted therapies.
Summary
Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data demonstrating that its lead candidate, Telomir-Zn, effectively suppresses tumor growth in models of prostate cancer and triple-negative breast cancer (TNBC). The study, published in the Journal of Oncology Research and Therapy, reveals that Telomir-Zn works by selectively modulating intracellular iron and copper levels, which in turn inhibits histone demethylases and depletes intracellular iron. This mechanism selectively kills iron-dependent TNBC cells while sparing normal cells, even at concentrations more than 50-fold higher than those affecting cancer cells. Additionally, the drug reactivated tumor-suppressor genes in a prostate cancer model, highlighting its potential as a targeted epigenetic therapy.
In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines and significantly reduced metastatic dissemination in HCC1806 xenografts. When combined with paclitaxel in BT-549 xenografts, the treatment produced significantly greater tumor reduction than either agent alone, although MDA-MB-231 xenografts showed no response, indicating tumor-specific differences in sensitivity. These findings provide the scientific foundation for advancing Telomir-Zn toward its planned Phase 1/2 clinical trial in TNBC under its active Investigational New Drug (IND) application. Telomir Pharmaceuticals, a clinical-stage biotechnology company, is developing small-molecule therapeutics targeting epigenetic and metabolic pathways in cancer. The company has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 trial in advanced or metastatic TNBC. For more details, visit the full press release at https://ibn.fm/mv3hn.
About Telomir Pharmaceuticals: The company is focused on modulating intracellular metal homeostasis and epigenetic regulation to combat cancer. Its lead program, Telomir-Zn, is designed to target these pathways. For the latest updates on TELO, visit their newsroom at https://ibn.fm/TELO. BioMedWire (BMW), a specialized communications platform, distributed this news. BMW covers developments in the biotechnology, biomedical, and life sciences sectors and is part of the Dynamic Brand Portfolio at IBN. For more information, visit BioMedWire's website.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Telomir-Zn Shows Promise in Prostate and Triple-Negative Breast Cancer
